AMARIN ANNOUNCES FIRST QUARTER 2007 RESULTS CONFERENCE CALL
Management to provide business and pipeline update
LONDON, United Kingdom, May 4, 2007 Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or
"Company") today announced that it will be discussing its first quarter 2007 results and providing a business
update in a conference call at 8.30 a.m. Eastern time/1.30 p.m. British summer time on Thursday, May 10 th
2007. Rick Stewart, Chief Executive Officer, Declan Doogan, President Research & Development and Alan
Cooke, President and Chief Financial Officer, can be heard by dialling (800) 968 7995 (tollfree) in the U.S. or
+1 (706) 679 8403 (toll) elsewhere. Conference ID 8011204.
The call will also be webcast live and a link will be on the company’s website at
www.amarincorp.com . Information on the company’s website is not part of this release.
For those who cannot listen to the live broadcast, a replay will be available shortly after the conference call in the
link on the company’s website www.amarincorp.com or by dialling (800) 642 1687 (tollfree) in the U.S. or +1
(706) 645 9291 (toll) elsewhere, and entering access code 8011204.
Amarin is committed to improving the lives of patients suffering from diseases of the central nervous
system. Our goal is to be a leader in the research, development and commercialization of novel drugs
that address unmet patient needs.
Amarin’s core development pipeline includes Miraxion for several therapeutic indications, an oral
formulation of apomorphine for treating patients with advanced Parkinson ’s disease, a nasal formulation
of lorazepam for treating emergency seizures and our proprietary pre-clinical combinatorial lipid
Amarin has its primary stock market listing in the U.S. on NASDAQ (“AMRN”) and secondary listings in
the U.K. and Ireland on AIM (“AMRN”) and IEX (“H2E”), respectively.
For press releases and other corporate information, visit the Amarin website at